Cardillo Giuseppe, Sera Francesco, Di Martino Marco, Graziano Paolo, Giunti Roberto, Carbone Luigi, Facciolo Francesco, Martelli Massimo
Thoracic Surgery Unit, Carlo Forlanini Hospital, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
Ann Thorac Surg. 2004 May;77(5):1781-5. doi: 10.1016/j.athoracsur.2003.10.089.
Bronchial carcinoid tumors show a favorable outcome. We sought to determinate the variables influencing the long-term survival of patients treated for bronchial carcinoid tumors.
We conducted a retrospective single institutional review of 163 patients surgically treated from January 1990 to April 2002. According to 1999 World Health Organization criteria, cases were segregated into typical (<2 mitoses per 2 mm, no necrosis) and atypical carcinoids (2 to 10 mitoses per 2 mm or necrosis).
There were 86 men and 77 women with a mean age of 49.5 +/- 11 years. Symptoms were present in 89 patients (54.6%). Operations included 145 formal lung resections (89%), 9 wedge resections (5.52%), 8 sleeve lobectomies (4.9%), and 1 segmental resection (0.61%) plus radical mediastinal lymphadenectomy in all cases. No operative mortality was reported. Histologic examination showed 121 (74.2%) typical carcinoids (107 N0 and 14 N1), and 42 (25.8%) atypical carcinoids (15 N0, 18 N1, 9 N2). All patients were included in a follow-up (median, 54 months; mean, 58 months; range, 4 to 150 months), which included total body computed tomographic scan and bronchoscopy every year. Overall 5-year survival was 90.3% with a mean survival time of 139 months (95% confidence interval, 133 to 145). In N0 patients with either typical or atypical carcinoid tumors, no disease-related mortality was reported (100% 5-year survival). In N1 patients, 5-year survival was 90.0% for those with typical carcinoids, and 78.8% for those with atypical carcinoids (p = 0.394). In atypical carcinoids with N2 disease, 5-year survival was 22.2%.
Prognosis in bronchial carcinoid tumors is more related to nodal status than to histologic subtype. In N0 and N1 patients no statistical significant difference has been found between typical and atypical subtype. However, N2 bronchial carcinoid tumors show a dismal prognosis.
支气管类癌肿瘤预后良好。我们试图确定影响支气管类癌肿瘤治疗患者长期生存的变量。
我们对1990年1月至2002年4月接受手术治疗的163例患者进行了单机构回顾性研究。根据1999年世界卫生组织标准,病例分为典型类癌(每2毫米<2个核分裂象,无坏死)和非典型类癌(每2毫米2至10个核分裂象或坏死)。
男性86例,女性77例,平均年龄49.5±11岁。89例患者(54.6%)有症状。手术包括145例正规肺切除术(89%)、9例楔形切除术(5.52%)、8例袖状肺叶切除术(4.9%)和1例节段性切除术(0.61%),所有病例均加行根治性纵隔淋巴结清扫术。未报告手术死亡病例。组织学检查显示121例(74.2%)为典型类癌(107例N0和14例N1),42例(25.8%)为非典型类癌(15例N0、18例N1、9例N2)。所有患者均纳入随访(中位时间54个月;平均时间58个月;范围4至150个月),每年进行全身计算机断层扫描和支气管镜检查。总体5年生存率为90.3%,平均生存时间为139个月(95%置信区间,133至145)。在N0期典型或非典型类癌肿瘤患者中,未报告与疾病相关的死亡病例(5年生存率100%)。在N1期患者中,典型类癌患者的5年生存率为90.0%,非典型类癌患者为78.8%(p = 0.394)。在N2期非典型类癌患者中,5年生存率为22.2%。
支气管类癌肿瘤的预后与淋巴结状态的关系比与组织学亚型的关系更大。在N0和N1期患者中,典型和非典型亚型之间未发现统计学显著差异。然而,N2期支气管类癌肿瘤预后不佳。